Results, doses and study populations, linked to the original research.
Clinicians and pharmacists who read trials like these can also be paid to judge whether AI models reason correctly about medicine: AITraining.jobs, a sister project of this site, explains what that expert review involves and how to start.
Direct comparisons
SURMOUNT-5 (nejm.org)
Peer-reviewed paper
Wegovy injection vs Zepbound
Adults with obesity, or overweight with a weight-related condition, without diabetes.
Treatment-regimen analysis, regardless of treatment adherence.
SURMOUNT-5: Mean weight change at 72 weeks. Treatment-regimen analysis, regardless of treatment adherence.
Treatment & dose
Change
Semaglutide (Wegovy)1.7 or 2.4 mg weekly injection
−13.7% (nejm.org)
Tirzepatide (Zepbound)10 or 15 mg weekly injection
−20.2% (nejm.org)
Tirzepatide produced greater mean weight reduction in this trial. Both groups used their maximum tolerated dose.
This trial did not test Wegovy tablets or Wegovy HD. It was not powered to establish a safety or tolerability advantage. Study averages do not predict an individual's result.
Read the paper (nejm.org)PubMed abstract (pubmed.ncbi.nlm.nih.gov)Sponsor's analysis details (investor.lilly.com)Reviewed
Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.
SURPASS-2: Mean HbA1c change at 40 weeks. Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.
Treatment & dose
Change
Semaglutide (Ozempic)1 mg weekly injection
−1.86 pp (nejm.org)
Tirzepatide (Mounjaro)5 mg weekly injection
−2.01 pp (nejm.org)
Tirzepatide (Mounjaro)10 mg weekly injection
−2.24 pp (nejm.org)
Tirzepatide (Mounjaro)15 mg weekly injection
−2.3 pp (nejm.org)
Each tirzepatide dose lowered HbA1c more than semaglutide 1 mg in this trial.
This trial did not compare Ozempic 2 mg or tablets. HbA1c changes are percentage points, not relative percentages or weight-loss results. Study averages do not predict an individual's result.
Read the paper (nejm.org)PubMed abstract (pubmed.ncbi.nlm.nih.gov)Sponsor's analysis details (investor.lilly.com)Reviewed
Adults with a BMI of at least 30, without diabetes.
1,407 participants · 72 weeks (doi.org/10.1016/S2213-8587(25)00226-8) · Randomized, double-blind, with placebo and active control
Mean weight change (% of body weight)
Treatment-policy analysis, accounting for treatment discontinuation.
STEP UP: Mean weight change at 72 weeks. Treatment-policy analysis, accounting for treatment discontinuation.
Treatment & dose
Change
Semaglutide (Wegovy)2.4 mg weekly injection
−15.6% (doi.org)
Semaglutide (Wegovy HD)7.2 mg weekly injection
−18.7% (doi.org)
PlaceboWeekly injection
−3.9% (doi.org)
The 7.2 mg dose produced greater mean weight reduction than 2.4 mg or placebo. Gastrointestinal events and altered skin sensations were more frequent at 7.2 mg.
All groups also received a lifestyle intervention. This trial did not study tablets. The 2.4 mg result is from STEP UP, not STEP 1. Study averages do not predict an individual's result.
Read the paper (doi.org)PubMed abstract (pubmed.ncbi.nlm.nih.gov)Reviewed
Treatment-regimen analysis, regardless of treatment adherence.
REDEFINE-4: Mean weight change at 84 weeks. Treatment-regimen analysis, regardless of treatment adherence.
Treatment & dose
Change
CagriSema2.4 mg / 2.4 mg weekly injection
−20.2% (novonordisk.com)
Tirzepatide15 mg weekly injection
−23.6% (novonordisk.com)
Mean weight change (% of body weight)
Efficacy analysis, assuming treatment adherence.
REDEFINE-4: Mean weight change at 84 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & dose
Change
CagriSema2.4 mg / 2.4 mg weekly injection
−23% (novonordisk.com)
Tirzepatide15 mg weekly injection
−25.5% (novonordisk.com)
CagriSema did not meet the trial's primary non-inferiority endpoint versus tirzepatide.
Figures are from the manufacturer's headline announcement. This record does not establish peer-reviewed publication. CagriSema is investigational in our reviewed catalog. Study averages do not predict an individual's result.
REIMAGINE 4: Mean weight change at 68 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & dose
Change
CagriSema2.4 mg / 2.4 mg weekly injection
−15.2% (sec.gov)
Tirzepatide (Mounjaro)15 mg weekly injection
−15.8% (sec.gov)
Mean HbA1c change (percentage points)
Efficacy analysis, assuming treatment adherence.
REIMAGINE 4: Mean HbA1c change at 68 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & dose
Change
CagriSema2.4 mg / 2.4 mg weekly injection
−1.9 pp (sec.gov)
Tirzepatide (Mounjaro)15 mg weekly injection
−2.2 pp (sec.gov)
CagriSema was non-inferior to tirzepatide 15 mg for weight reduction but did not meet non-inferiority for HbA1c reduction, the trial's two primary endpoints.
Figures are from Novo Nordisk's half-year report, on the analysis that assumes every participant stayed on treatment; no treatment-regimen result or peer-reviewed publication yet. ClinicalTrials.gov lists this trial (NCT06221969) without its REIMAGINE 4 name. CagriSema is investigational. Study averages do not predict an individual's result.
Read the announcement (sec.gov)Sponsor's analysis details (clinicaltrials.gov)Reviewed
REIMAGINE 5: Mean weight change at 60 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & dose
Change
CagriSema1.0 mg / 1.0 mg weekly injection
−12.4% (novonordisk.com)
Tirzepatide (Mounjaro)5 mg weekly injection
−9.1% (novonordisk.com)
Mean HbA1c change (percentage points)
Analysis not stated in the announcement.
REIMAGINE 5: Mean HbA1c change at 60 weeks. Analysis not stated in the announcement.
Treatment & dose
Change
CagriSema1.0 mg / 1.0 mg weekly injection
−1.71 pp (novonordisk.com)
Tirzepatide (Mounjaro)5 mg weekly injection
−1.67 pp (novonordisk.com)
CagriSema 1.0 mg / 1.0 mg was superior to tirzepatide 5 mg for weight reduction and non-inferior for HbA1c reduction.
Neither arm used the dose most people end on: 5 mg is tirzepatide's lowest maintenance dose, and 1.0 mg / 1.0 mg is not the CagriSema dose filed with the FDA. Figures are from Novo Nordisk's announcement, not a peer-reviewed paper. CagriSema is investigational. Study averages do not predict an individual's result.
Read the announcement (novonordisk.com)Sponsor's analysis details (clinicaltrials.gov)Reviewed
TRANSCEND-T2D-2: Mean HbA1c change at 80 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & dose
Change
Retatrutide9 mg weekly injection
−2.2 pp (prnewswire.com)
Retatrutide12 mg weekly injection
−2.2 pp (prnewswire.com)
Semaglutide (Ozempic)2 mg weekly injection
−1.8 pp (prnewswire.com)
Mean weight change (% of body weight)
Efficacy analysis, assuming treatment adherence.
TRANSCEND-T2D-2: Mean weight change at 80 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & dose
Change
Retatrutide9 mg weekly injection
−19.5% (prnewswire.com)
Retatrutide12 mg weekly injection
−20.9% (prnewswire.com)
Semaglutide (Ozempic)2 mg weekly injection
−9.4% (prnewswire.com)
Both retatrutide doses lowered HbA1c more than Ozempic 2 mg, its highest approved dose, and produced about twice the weight loss. Discontinuation for adverse events was 4.8% (9 mg) and 7.9% (12 mg) vs 2.7%.
Figures are from Lilly's topline announcement, on the analysis that assumes every participant stayed on treatment; not yet peer-reviewed. This trial did not test Ozempic tablets or Wegovy. Retatrutide is investigational. Study averages do not predict an individual's result.
Read the announcement (prnewswire.com)Sponsor's analysis details (clinicaltrials.gov)Reviewed
These results come from different studies with different participants, durations, doses, and analyses. They do not establish which treatment is best for you. Medications are listed alphabetically.
Bar scale: 0–30% body-weight reduction. ≈ marks an approximation from kilograms. A trial estimate is not a prediction of your outcome.
≈−4% (diabetesjournals.org/care/article/33/6/1255/27340/DURATION-1-Exenatide-Once-Weekly-Produces) (-4.1 kg (~4% of the 102 kg baseline) at 52 wks · DURATION-1 · 2 mg weekly (Bydureon))
The same trial also reported −20.4% (novonordisk.com/news-and-media/news-and-ir-materials/news-details.html) using the treatment-policy analysis, which accounts for treatment discontinuation. This is the estimate used when matching your priorities.
The same trial also reported −25% (nejm.org/doi/full/10.1056/NEJMoa2604169) using the treatment-regimen analysis, which accounts for treatment discontinuation. This is the estimate used when matching your priorities.
The same trial also reported −13% (nejm.org/doi/full/10.1056/NEJMoa2600751) using the treatment-regimen analysis, which accounts for treatment discontinuation. This is the estimate used when matching your priorities.
Selected weight-change results are not a systematic review of all benefits and risks. Open each medication for additional evidence and safety information. Sources & methodology.
From PubMed
The newest GLP-1 trials and reviews
Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43035096)
Randomized trial · Tirzepatide · JAMA · Nov 15, 2026 · Kelly AS et al.
Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m<sup>2</sup> Treated by Semaglutide: A 60-Week Randomized Placebo-Controlled Trial (pubmed.ncbi.nlm.nih.gov/43035836)
Randomized trial · Semaglutide · Int J Eat Disord · Nov 15, 2026 · Allison KC et al.
Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial (pubmed.ncbi.nlm.nih.gov/43033821)
Randomized trial · Semaglutide · Lancet Diabetes Endocrinol · Nov 14, 2026 · Wharton S et al.
Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review (pubmed.ncbi.nlm.nih.gov/43034163)
Systematic review · Semaglutide · BMC Oral Health · Nov 14, 2026 · Muknickas D et al.
Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/43025465)
Meta-analysis · Tirzepatide · Diabetes Res Clin Pract · Nov 13, 2026 · Li S et al.
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study (pubmed.ncbi.nlm.nih.gov/43014327)
Randomized trial · Pemvidutide · Lancet Gastroenterol Hepatol · Nov 11, 2026 · Noureddin M et al.
First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43013292)
Randomized trial · Semaglutide · JAMA Cardiol · Nov 11, 2026 · Marx N et al.
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial (pubmed.ncbi.nlm.nih.gov/43014326)
Randomized trial · Semaglutide · Lancet · Nov 11, 2026 · Mosenzon O et al.
Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43012507)
Randomized trial · Tirzepatide · Arthritis Rheumatol · Nov 11, 2026 · Merola JF et al.
Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial (pubmed.ncbi.nlm.nih.gov/43003902)
Randomized trial · Tirzepatide · Nat Med · Nov 9, 2026 · Green DJ et al.
Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial (pubmed.ncbi.nlm.nih.gov/43003106)
Randomized trial · Survodutide · Lancet · Nov 9, 2026 · Bozkurt B et al.
Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA) (pubmed.ncbi.nlm.nih.gov/43002161)
Randomized trial · Orforglipron · JAMA · Nov 9, 2026 · Malhotra A et al.
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Updated automatically
What just changed in the trial registry
TrialSemaglutide study now recruiting (was not yet recruiting): GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study (clinicaltrials.gov/study/NCT07588984)
TrialResults posted for a Liraglutide study: SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (clinicaltrials.gov/study/NCT04775082)
TrialNew Survodutide study registered: A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity (clinicaltrials.gov/study/NCT07940244)
TrialVK2735 study now recruiting (was not yet recruiting): Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) (clinicaltrials.gov/study/NCT07868939)
TrialVK2735 study now recruiting (was not yet recruiting): Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) (clinicaltrials.gov/study/NCT07868835)
TrialNew Semaglutide study registered: Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults (clinicaltrials.gov/study/NCT07935200)
TrialSemaglutide study now completed (was active, not recruiting): A Study of BGM0504 in Participants With Type 2 Diabetes (clinicaltrials.gov/study/NCT06716216)
TrialNew Semaglutide study registered: GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications (clinicaltrials.gov/study/NCT07932119)
TrialTirzepatide study now recruiting (was not yet recruiting): Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial (clinicaltrials.gov/study/NCT07734792)
TrialNew Tirzepatide study registered: Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity (clinicaltrials.gov/study/NCT07931235)
Europe PMC search matches, listed alphabetically. RCT-tagged publications are not necessarily unique clinical trials. Publication types can overlap, and searches can mention more than one medicine.
All search matches33 (europepmc.org/search) (VK2735: All search matches)
These are search matches, not a count of independent trials or proof of benefit. Publication types overlap. Results may include animal research, articles mentioning several ingredients, or retracted work. Counts do not assess study quality and may change after retrieval.
NCT06045221Completed1,698 enrolledCompleted Aug 22, 2025
Registered primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]
Trial averages do not predict individual outcomes. Review the studied dose, population, duration, analysis, and safety findings with a prescribing clinician. Informational only, not medical advice. Confirm with a clinician and the current FDA label.